Vigabatrin monotherapy for infantile spasms

References

• Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia45(11), 1416–1428 (2004).
   PubMed Web of Science ®Google Scholar
• Pellock JM, Hrachovy R, Shinnar S et al. Infantile spasms: a U.S. consensus report. Epilepsia51(10), 2175–2179 (2010).
   PubMed Web of Science ®Google Scholar
• Cowan LD, Hudson LS. The epidemiology and natural history of infantile spasms. J. Child Neurol.6(4), 355–364 (1991).
   PubMed Web of Science ®Google Scholar
• Granström ML, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia40(7), 950–957 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen-Sadan S, Kramer U, Ben-Zeev B et al. Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. Eur. J. Neurol.16(4), 482–487 (2009).
   PubMed Web of Science ®Google Scholar
• Osborne JP, Lux AL, Edwards SW et al. The underlying etiology of infantile spasms (West syndrome): information from the United Kingdom infantile spasms study (UKISS) on contemporary causes and their classification. Epilepsia51(10), 2168–2174 (2010).
   PubMed Web of Science ®Google Scholar
• Dulac O, Plouin P, Jambaque I. Predicting favorable outcome in idiopathic West syndrome. Epilepsia34(4), 747–756 (1993).
   PubMed Web of Science ®Google Scholar
• Lagae L, Verhelst H, Ceulemans B et al. Treatment and long term outcome in West syndrome: the clinical reality. A multicentre follow up study. Seizure19(3), 159–164 (2010).
   PubMed Web of Science ®Google Scholar
• Kivity S, Lerman P, Ariel R, Danziger Y, Mimouni M, Shinnar S. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia45(3), 255–262 (2004).
   PubMed Web of Science ®Google Scholar
• Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res.26, 389–395 (1997).
   PubMed Web of Science ®Google Scholar
• Chiron C, Dulac O, Luna L et al. Vigabatrin in infantile spasms. Lancet335, 363–364 (1990).
   PubMed Web of Science ®Google Scholar
• Pesaturo KA, Spooner LM, Belliveau P. Vigabatrin for infantile spasms. Pharmacotherapy31(3), 298–311 (2011).
   PubMed Web of Science ®Google Scholar
• Lerner JT, Salamon N, Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr. Dis. Treat.6, 731–740 (2010).
   PubMed Web of Science ®Google Scholar
• Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia38(12), 1270–1274 (1997).
   PubMed Web of Science ®Google Scholar
• Appleton RE, Peters ACB, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia40(11), 1627–1633 (1999).
   PubMed Web of Science ®Google Scholar
• Elterman RD, Shields WD, Mansfield KA, Nagakawa J; the US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology57(8), 1416–1421 (2001).
   PubMed Web of Science ®Google Scholar
• Elterman RD, Shields WD, Bittman RM, Torri SA, Sagar SM, Collins SD. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J. Child Neurol.25(11), 1340–1347 (2010).
   PubMed Web of Science ®Google Scholar
• Lux AL, Edwards SW, Hancock E et al. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet364, 1773–1778 (2004).
   PubMed Web of Science ®Google Scholar
• Lux AL, Edwards SW, Hancock E et al. The United Kingdom infantile spasms study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol.4(11), 712–717 (2005).
   PubMed Web of Science ®Google Scholar
• Darke K, Edwards SW, Hancock E et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch. Dis. Child.95(5), 382–386 (2010).
   PubMed Web of Science ®Google Scholar
• Camposano SE, Major P, Halpern E, Thiele EA. Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile. Epilepsia49(7), 1186–1191 (2008).
   PubMed Web of Science ®Google Scholar
• Karvelas G, Lortie A, Scantlebury MH, Duy PT, Cossette P, Carmant L. A retrospective study on aetiology based outcome of infantile spasms. Seizure18(3), 197–201 (2009).
   PubMed Web of Science ®Google Scholar
• Ibrahim S, Gulab S, Ishaque S, Saleem T. Clinical profile and treatment of infantile spasms using vigabatrin and ACTH – a developing country perspective. BMC Pediatr.10(1), 1 (2010).
   PubMed Web of Science ®Google Scholar
• Mohamed BP, Scott RC, Desai N, Gutta P, Patil S. Seizure outcome in infantile spasms – a retrospective study. Epilepsia52(4), 746–752 (2011).
   PubMed Web of Science ®Google Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ314, 180–181 (1997).
   PubMed Web of Science ®Google Scholar
• Kälviäinen R, Nousiainen I, Mäntyjarvi M et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology53(5), 922–926 (1999).
   PubMed Web of Science ®Google Scholar
• Maguire MJ, Hemming K, Wild JM, Hutton JL, Marson AG. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia51(12), 2423–2431 (2010).
   PubMed Web of Science ®Google Scholar
• Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia50(2), 206–216 (2009).
   PubMed Web of Science ®Google Scholar
• Wohlrab G, Leiba H, Kastle R et al. Vigabatrin therapy in infantile spasms: solving one problem and inducing another? Epilepsia50(8), 2006–2008 (2009).
   PubMed Web of Science ®Google Scholar
• Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M. The Hospital for Sick Children, Toronto, longitudinal ERG study of children on vigabatrin. Doc. Ophthalmol.104, 133–149 (2002).
   PubMedGoogle Scholar
• Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia50(2), 163–173 (2009).
   PubMed Web of Science ®Google Scholar
• Durbin S, Mirabella G, Buncic JR, Westall CA. Reduced grating acuity associated with retinal toxicity in children with infantile spasms on vigabatrin therapy. Invest. Ophthalmol. Vis. Sci.50(8), 4011–4016 (2009).
   PubMed Web of Science ®Google Scholar
• Lawthom C, Smith PE, Wild JM. In utero exposure to vigabatrin: no indication of visual field loss. Epilepsia50(2), 318–321 (2009).
   PubMed Web of Science ®Google Scholar
• Sorri I, Herrgard E, Viinikainen K, Paakkonen A, Heinonen S, Kalviainen R. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero. Epilepsy Res.65(1–2), 117–120 (2005).
   PubMed Web of Science ®Google Scholar
• Best JL, Acheson JF. The natural history of vigabatrin associated visual field defects in patients electing to continue their medication. Eye19(1), 41–44 (2005).
   PubMed Web of Science ®Google Scholar
• Kinirons P, Cavalleri GL, O’Rourke D et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia47(2), 311–317 (2006).
   PubMed Web of Science ®Google Scholar
• Jammoul F, Wang Q, Nabbout R. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann. Neurol.65(1), 98–107 (2009).
   PubMed Web of Science ®Google Scholar
• Sorri I, Brigell MG, Malyusz M, Mahlamaki E, de Meynard C, Kalviainen R. Is reduced ornithine-aminotransferase activity the cause of vigabatrin-associated visual field defects? Epilepsy Res.92(1), 48–53 (2010).
   PubMed Web of Science ®Google Scholar
• Pellock JM, Faught R, Sergott RC et al. Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav.22(4), 710–717 (2011).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia41(2), 148–157 (2000).
   PubMed Web of Science ®Google Scholar
• Pearl PL, Vezina LG, Saneto RP et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia50(2), 184–194 (2009).
   PubMed Web of Science ®Google Scholar
• Wheless JW, Carmant L, Bebin M et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia50(2), 195–205 (2009).
   PubMed Web of Science ®Google Scholar
• Dracopoulos A, Widjaja E, Raybaud C, Westall CA, Snead OC 3rd. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia51(7), 1297–1304 (2010).
   PubMed Web of Science ®Google Scholar
• Horton M, Rafay M, Del Bigio MR. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J. Child Neurol.24(12), 1543–1546 (2009).
   PubMed Web of Science ®Google Scholar
• Perheentupa J, Riikonen R, Dunkel L, Simell O. Adrenocortical hyporesponsiveness after treatment with ACTH of infantile spasms. Arch. Dis. Child.61(8), 750–753 (1986).
   PubMed Web of Science ®Google Scholar
• Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. Arch. Dis. Child.55(9), 664–672 (1980).
   PubMed Web of Science ®Google Scholar
• Hrachovy RA, Frost JD, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J. Pediatr.124(5), 803–806 (1994).
   PubMed Web of Science ®Google Scholar
• Heiskala H, Riikonen R, Santavuori P et al. West syndrome: individualized ACTH therapy. Brain Dev.18, 456–460 (1996).
   PubMed Web of Science ®Google Scholar
• Sergott RC, Wheless JW, Smith MC et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-Ophthalmology34(1), 20–35 (2010).
   Web of Science ®Google Scholar
• Capovilla G, Beccaria F, Montagnini A et al. Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia44(8), 1085–1088 (2003).
   PubMed Web of Science ®Google Scholar
• Nabbout R, Melki I, Gerbaka B, Dulac O, Akatcherian C. Infantile spasms in Down syndrome: good response to a short course of vigabatrin. Epilepsia42(12), 1580–1583 (2001).
   PubMed Web of Science ®Google Scholar
• Jambaqué I, Chiron C, Dumas C, Mumford J, Dulac O. Mental and behavioral outcome of infantile epilepsy treated by vigabatrin in tuberous sclerosis patients. Epilepsy Res.38(2–3), 151–160 (2000).
   PubMed Web of Science ®Google Scholar
• Kröll-Seger J, Kaminska A, Moutard ML, Guët A, Dulac O, Chiron C. Severe relapse of infantile spasms after vigabatrin withdrawal: for how long should we treat symptomatic infantile spasms? Epilepsia48(3), 612–613 (2007).
   PubMed Web of Science ®Google Scholar
• Humphrey A, Neville BG, Clarke A, Bolton PF. Autistic regression associated with seizure onset in an infant with tuberous sclerosis. Dev. Med. Child Neurol.48(7), 609–611 (2006).
   PubMed Web of Science ®Google Scholar
• Jambaqué I, Chiron C, Dulac O, Raynaud C, Syrota P. Visual inattention in West syndrome: a neuropsychological and neurofunctional imaging study. Epilepsia34(4), 692–700 (1993).
   PubMed Web of Science ®Google Scholar
• Mirabella G, Morong S, Buncic JR et al. Contrast sensitivity is reduced in children with infantile spasms. Invest. Ophthalmol. Vis. Sci.48(8), 3610–3615 (2007).
   PubMed Web of Science ®Google Scholar
• Wild JM, Robson CR, Jones AL, Cunliffe IA, Smith PE, Philip EM. Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest. Ophthalmol. Vis. Sci.47(3), 917–924 (2006).
   PubMed Web of Science ®Google Scholar
• Naili F, Boucart M, Derambure P, Arndt C. Visual impairment at large eccentricity in participants treated by vigabatrin: visual, attentional or recognition deficit? Epilepsy Res.87(2–3), 213–222 (2009).
   PubMed Web of Science ®Google Scholar
• Desguerre I, Pinton F, Nabbout R et al. Infantile spasms with basal ganglia MRI hypersignal may reveal mitochondrial disorder due to T8993G MT DNA mutation. Neuropediatrics34(5), 265–269 (2003).
   PubMed Web of Science ®Google Scholar
• Campen CJ, Porter BE. Subependymal giant cell astrocytoma (SEGA) treatment update. Curr. Treat. Options Neurol.13, 380–385 (2011).
   PubMed Web of Science ®Google Scholar
• Raffo E, Coppola A, Ono T, Briggs SW, Galanopoulou AS. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol. Dis.43, 322–329 (2011).
   PubMed Web of Science ®Google Scholar